Live Breaking News & Updates on Director Richard Barry|Page 5

Stay updated with breaking news from Director richard barry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FY2023 Earnings Forecast for Sarepta Therapeutics, Inc. Issued By Zacks Research (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Investment analysts at Zacks Research lifted their FY2023 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued to investors on Tuesday, January 2nd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($6.77) per share for the year, […] ....

New Zealand General , New Zealand , Douglass Ingram , Richard Barry , Wellington Management Group , Needham Company , Securities Exchange Commission , Sarepta Therapeutics Inc , Vanguard Group Inc , Zacks Research , Manufacturers Life Insurance Company , Jpmorgan Chase Co , Capital Partners , Sarepta Therapeutics , Free Report , Sarepta Therapeutic , Get Free Report , Therapeutics Trading Down , Director Richard Barry , Exchange Commission , Management Group , Sarepta Therapeutics Daily , Nasdaq Srpt , Earnings Estimates ,

Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Citigroup

Citigroup assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage issued a buy rating and a $113.00 price target on the biotechnology company’s stock. A number of other brokerages have also recently weighed in on SRPT. Barclays dropped their price target on […] ....

Volgogradskaya Oblast , Richard Barry , Douglass Ingram , Neuberger Berman Group , Acadian Asset Management , A Davidson , Cantor Fitzgerald , Royal Bank , Capital Management , Sarepta Therapeutics Inc , Securities Exchange Commission , Sarepta Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Richard Barry , Exchange Commission , Asset Management , Berman Group , Sarepta Therapeutics Daily , Nasdaq Srpt , Initiated Coverage , Citigroup Inc ,

Camber Capital Management LP Sells 350,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Camber Capital Management LP trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 46.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 400,000 shares of the biotechnology company’s stock after selling 350,000 shares during the period. […] ....

New Zealand General , New Zealand , Richard Barry , Douglass Ingram , Royal Bank , Sarepta Therapeutics Inc , Exchange Commission , Wellington Management Group , Norges Bank , Boxer Capital , Cantor Fitzgerald , York Mellon Corp , Camber Capital Management , Sarepta Therapeutics , Free Report , Capital Management , Management Group , Sigma Advisers , New York Mellon Corp , Director Richard Barry , Get Free Report , Visit Holdingschannel , Sarepta Therapeutics Daily , Nasdaq Srpt , Sec Filings , Hedge Fund Holdings ,

Artia Global Partners LP Increases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Artia Global Partners LP raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 28.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,162 shares of the biotechnology company’s stock after buying an additional 17,162 shares during the […] ....

Douglass Ingram , Richard Barry , Jennison Associates , Securities Exchange Commission , Exchange Commission , Sarepta Therapeutics Company Profile , York Mellon Corp , Tekla Capital Management , Cantor Fitzgerald , Sarepta Therapeutics Inc , Jpmorgan Chase Co , First Horizon Advisors Inc , Morgan Stanley , Artia Global Partners , Sarepta Therapeutics , Free Report , Global Partners , Horizon Advisors , Montreal Can , Capital Management , New York Mellon Corp , Get Free Report , Director Richard Barry , Sarepta Therapeutics Daily , Nasdaq Srpt , Sec Filings ,